VIEW yields 606.06% · ABBV yields 3.12%● Live data
📍 VIEW pulled ahead of the other in Year 1
Combined, VIEW + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VIEW + ABBV for your $10,000?
View, Inc., a technology company, manufactures and sells smart building products. Its product portfolio includes View Smart Glass that comprise electrochromic glass panels in the form of insulating glass units; and View Net, a cloud-connected network infrastructure offering that can incorporate and power smart building devices. The company's products also include View Immersive Experiences, which transforms View Smart Glass windows into transparent, digital, and interactive surfaces; View Sense modules to measure and optimize light, humidity, temperature, air quality, dust, and noise; View Smart Protect, an intrusion detection solution that can be deployed on View Smart Glass windows to improve the security of a building by detecting glass breakage; View Secure Edge, a plug-and-play edge-to-cloud solution that enables IT and digital innovation teams to securely connect new and existing buildings to the cloud; View Remote Access, a secure access portal that enables IT teams to reduce the cost and cybersecurity risks of maintaining smart buildings; and View Building Performance, a configurable application and web-based tool that enables building managers to measure, optimize, and automate building performance; and View Workplace Experience, a configurable application and web-based tool that enables corporate facilities managers to create productive workplaces. It sells its products to real estate industry, including commercial offices, airports, hospitals and healthcare facilities, multi-family residential, and educational buildings. The company is headquartered in Milpitas, California.
Full VIEW Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.